Patents Assigned to Pfizer Inc.
  • Patent number: 4551452
    Abstract: Certain enol ether derivatives of oxicams (1,1-dioxides of N-heteroaryl-4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxamides and N-heteroaryl-4-hydroxy-2-methyl-2H-thieno[2,3-e]-1,2-thiazine-3-carboxamid es) are useful as prodrugs of these antiinflammatory compounds.
    Type: Grant
    Filed: May 2, 1984
    Date of Patent: November 5, 1985
    Assignee: Pfizer Inc.
    Inventor: Anthony Marfat
  • Patent number: 4550164
    Abstract: Isobutylene carbonate and certain 1-substituted piperazine compounds are reacted in a process that forms 2-methyl-2-hydroxypropyl 4-substituted piperazine-1-carboxylate compounds which are medicinal agents or synthetic intermediates for such agents. The features of the process allow the preparation of an essentially pure 2-methyl-2-hydroxypropyl carboxylate compound.
    Type: Grant
    Filed: April 24, 1981
    Date of Patent: October 29, 1985
    Assignee: Pfizer Inc.
    Inventors: Irving M. Goldman, Donald E. Kuhla, Constantine Sklavounos
  • Patent number: 4548935
    Abstract: Dihydropyridine anti-ischaemic and anti-hypertensive agents of the formula: ##STR1## and their pharmaceutically acceptable salts; wherein R is aryl or heteroaryl; R.sup.1 and R.sup.2 are each independently C.sub.1 -C.sub.4 or 2-methoxyethyl; n is 1 or 2; m is 1, 2 or 3; X is a 5 or 6 membered aromatic heterocyclic group which is linked to the adjacent alkoxymethyl group by a ring carbon atoms thereof; and Z is a group--NR.sup.3 R.sup.4 or a 5 to 6 membered nitrogen containing heterocyclic group; where R.sup.3 is H or C.sub.1 -C.sub.4 alkyl; R.sup.4 is H, C.sub.1 -C.sub.4 alkyl, CO(C.sub.1 -C.sub.4 alkyl), COCF.sub.3, CONR.sup.5 R.sup.6, SO.sub.2 (C.sub.1 -C.sub.4 alkyl) or a heterocyclic or SO.sub.2 -heterocyclic group, wherein the heterocyclic group is optionally substituted; R.sup.5 and R.sup.6 and each independently H or C.sub.1 -C.sub.4 alkyl or taken together with the nitrogen atom to which they are attached, they form a pyrrolidinyl, piperidyl, morpholino, piperazinyl or N-(C.sub.1 -C.sub.
    Type: Grant
    Filed: January 16, 1985
    Date of Patent: October 22, 1985
    Assignee: Pfizer Inc.
    Inventors: David Alker, Peter E. Cross, Simon F. Campbell
  • Patent number: 4547502
    Abstract: 1,4-Dihydropyridine derivatives of the formula ##STR1## and their pharmaceutically acceptable acid addition salts; where:R is aryl or heteroaryl;R.sup.1 and R.sup.2 are each independently C.sub.1 -C.sub.4 alkyl or2-methoxyethyl;Y is --(CH.sub.2).sub.2 --, --CH.sub.2).sub.3 --, --CH.sub.2 CH(CH.sub.3)-- or --CH.sub.2 C(CH.sub.3).sub.2 --;R.sup.3 is ##STR2## , and pharmaceutical compositions containing such compounds, have utility as anti-ischaemic and antihypertensive agents.
    Type: Grant
    Filed: September 1, 1983
    Date of Patent: October 15, 1985
    Assignee: Pfizer Inc.
    Inventors: Simon F. Campbell, Peter E. Cross, John K. Stubbs
  • Patent number: 4547501
    Abstract: A series of novel [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives wherein the amine group is optionally substituted with lower alkyl, phenylalkyl having up to three carbon atoms in the alkyl moiety or alkanoyl having from two to five carbon atoms, or the amine group alternatively completes a piperazino ring, the quinoxaline ring is optionally substituted with fluorine, chlorine, bromine or methoxy, and the triazolo ring is optionally substituted with lower alkyl, lower perfluoroalkyl or phenyl are disclosed. These novel compounds are useful for treatment of symptoms associated with depression. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of depression and fatigue.
    Type: Grant
    Filed: October 10, 1984
    Date of Patent: October 15, 1985
    Assignee: Pfizer Inc.
    Inventor: Reinhard Sarges
  • Patent number: 4547523
    Abstract: A new polyether antibiotic has been isolated from fermentations of a new microorganism of the genus Streptomyces. This new microorganism is designated as N478-13 and it has ben named Streptomyces routienii Huang sp. nov., (ATCC 39446). The new antibiotic exhibits antibacterial activity against a variety of gram-positive bacteria; it can be used to control swine dysentery; and it promotes increased efficiency of feed utilization (i.e. promotes increased growth) in swine and ruminants.
    Type: Grant
    Filed: November 7, 1983
    Date of Patent: October 15, 1985
    Assignee: Pfizer Inc.
    Inventors: Walter D. Celmer, Walter P. Cullen, Hiroshi Maeda, Junsuke Tone
  • Patent number: 4547559
    Abstract: Substantially homogeneous acrylate/maleate copolymers of number average molecular weight of 500 to 5000 are prepared by copolymerizing 35 to 65 mole percent acrylic or methacrylic acid with 65 to 35 mole percent maleic anhydride at 80.degree. to 150.degree. C. in the presence of a polymerization initiator and a chain-transfer solvent such that both the monomers and the formed polymer remain in solution and the mole ratio of the acrylic or methacrylic acid monomer to the maleic anhydride monomer in the solvent is maintained below about 0.2 throughout the polymerization. The copolymers in hydrolyzed form are employed at a level of from about 0.1 to 100 ppm for prevention of alkaline calcium and magnesium scale formation, such as during seawater evaporative desalination.
    Type: Grant
    Filed: March 18, 1983
    Date of Patent: October 15, 1985
    Assignee: Pfizer Inc.
    Inventor: Stanley W. Walinsky
  • Patent number: 4546113
    Abstract: Diamidines of the formula ##STR1## wherein X is a propylene, isobutylene, guanidine, pyrrole, tetrazole, imidazole or substituted imidazole group; and 2-[4-(2-imidazolinyl)phenyl]-6-(2-imidazolinyl)indole, are useful in the treatment of certain protozoal infections in mammals, particularly in cattle.
    Type: Grant
    Filed: April 14, 1983
    Date of Patent: October 8, 1985
    Assignee: Pfizer Inc.
    Inventor: Edward A. Glazer
  • Patent number: 4543334
    Abstract: An antibiotic complex, consisting of one major and two minor components, has been isolated from fermentation of a new Streptomyces culture. The components from the complex are three new macrolides which are active as antibacterial agents against certain gram-negative and gram-positive microorganisms.
    Type: Grant
    Filed: December 16, 1983
    Date of Patent: September 24, 1985
    Assignee: Pfizer Inc.
    Inventors: Walter D. Celmer, Walter P. Cullen, Hiroshi Maeda, Junsuke Tone
  • Patent number: 4542132
    Abstract: A series of novel 4-piperidino-6,7-dimethoxyquinazoline compounds, further substituted on the piperidino group, and the pharmaceutically-acceptable salts thereof, possess cardiac stimulating activity in mammals. They are useful in the curative or prophylactic treatment of cardiac conditions, in particular heart failure.
    Type: Grant
    Filed: July 31, 1984
    Date of Patent: September 17, 1985
    Assignee: Pfizer Inc.
    Inventors: Simon F. Campbell, Albert A. Jaxa-Chamiec, David A. Roberts
  • Patent number: 4540687
    Abstract: 6-(2-Amino-2-[4-acyloxyphenyl]acetamido)penicillanoyloxymethyl esters of penicillanic acid 1,1-dioxide are useful as antibacterial agents. Derivatives of the aforesaid antibacterial agents which have an amino protecting group on the amino function in the 2-amino-2-(4-acyloxyphenyl)acetamido side chain are useful intermediates to the antibacterial agents themselves.
    Type: Grant
    Filed: August 12, 1982
    Date of Patent: September 10, 1985
    Assignee: Pfizer Inc.
    Inventor: Michael S. Kellogg
  • Patent number: 4539322
    Abstract: 1,4-Dihydropyridine derivatives of the formula: ##STR1## and their pharmaceutically acceptable acid addition salts; where R is aryl or heteroaryl;R.sup.1 and R.sup.2 are each independently C.sub.1 -C.sub.4 alkyl or2-methoxyethyl;Y is --(CH.sub.2).sub.2 --, --(CH.sub.2).sub.3 --, --CH.sub.2 CH(CH.sub.3)-- or --CH.sub.2 C(CH.sub.3).sub.2 --;R.sup.3 is hydrogen or an organic substituentare useful in treating or preventing heart conditions or hypertension.
    Type: Grant
    Filed: September 1, 1983
    Date of Patent: September 3, 1985
    Assignee: Pfizer Inc.
    Inventors: Simon F. Campbell, Peter E. Cross, John K. Stubbs
  • Patent number: 4536518
    Abstract: Novel cis-isomeric derivatives of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine are useful as antidepressant agents. These novel compounds act to block the synaptosomal uptake of serotonin (5-hydroxy-tryptamine), thereby alleviating serotonin abnormalities at central receptor sites. The preferred embodiment is the enantiomer cis-(1S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenam ine and its pharmaceutically acceptable acid addition salts.
    Type: Grant
    Filed: November 1, 1979
    Date of Patent: August 20, 1985
    Assignee: Pfizer Inc.
    Inventors: Willard M. Welch, Jr., Charles A. Harbert, B. Kenneth Koe, Allen R. Kraska
  • Patent number: 4536396
    Abstract: Combination of 6-methyl-1,2,3-oxathiazin-4(3H)-one-2,2-dioxide (acesulfame) with 3-(L-aspartyl-D-alaninamido)-2,2,4,4-tetramethylthietane masks the bitter taste of the oxathiazine and at the same time provides synergistic sweetness over a range of concentrations.
    Type: Grant
    Filed: September 6, 1983
    Date of Patent: August 20, 1985
    Assignee: Pfizer Inc.
    Inventors: Charles R. Stephens, Jr., Anibal Torres
  • Patent number: 4536573
    Abstract: A novel compound of the formula ##STR1## wherein R is hydrogen, benzyl or (C.sub.1 -C.sub.3)alkyl; R.sup.1 is benzyl or (C.sub.1 -C.sub.4)alkyl and Z.sup.1 taken together with --C.dbd.
    Type: Grant
    Filed: May 11, 1984
    Date of Patent: August 20, 1985
    Assignee: Pfizer Inc.
    Inventor: Joseph A. Kardys
  • Patent number: 4536393
    Abstract: 6-alpha- and 6-beta-(Aminomethyl)penicillanic acid, 1,1-dioxide esters which are hydrolyzable under physiological conditions, particularly those wherein the ester radical is 1H-isobenzofuran-3-on-1-yl or (5-methyl-1,3-dioxol-2-on-4-yl)methyl, and an improved process and intermediates used in their synthesis.
    Type: Grant
    Filed: February 6, 1984
    Date of Patent: August 20, 1985
    Assignee: Pfizer Inc.
    Inventor: Wayne E. Barth
  • Patent number: 4535084
    Abstract: A series of 4-(2-hydroxyethylthiomethyl)pyridines and related compounds, and their pharmaceutically acceptable acid addition salts, having immunoregulatory activity are disclosed. Preferred compounds include 4-(2-hydroxyethylthiomethyl)pyridine itself, as well as 4-(2-hydroxy-1-propylthiomethyl)pyridine, 4-(3-hydroxy-2-butylthiomethyl)pyridine, the acetate esters corresponding to the above compounds, and 4-(2,3-dihydroxy-1-propylthiomethyl)pyridine.
    Type: Grant
    Filed: March 18, 1983
    Date of Patent: August 13, 1985
    Assignee: Pfizer Inc.
    Inventors: Joseph G. Lombardino, Charles A. Harbert
  • Patent number: 4535081
    Abstract: Antiallergy and antiulcer agents having the formula (I), ##STR1## and their pharmaceutically acceptable salts, wherein R.sub.1 and R.sub.2 taken separately are each hydrogen or lower alkyl; and R.sub.1 and R.sub.2 taken together are alkylene of 3-9 carbon atoms or phenylalkylene of 9-11 carbon atoms, with the proviso that the ring so formed is between 5- and 8-membered; acids of the formula (II), ##STR2## wherein R.sub.1 and R.sub.2 are as defined above and R.sub.3 is hydrogen, which are useful as intermediates for compounds of the formula (I), but in many instances also possess the same useful biological activity as do formula I compounds; and intermediates of the formula II wherein R.sub.1 and R.sub.2 are defined as above, and R.sub.3 is alkyl of 1 to 4 carbon atoms, carbalkoxy of 2 to 5 carbon atoms, carbophenoxy or carbobenzoxy, are also described.
    Type: Grant
    Filed: August 17, 1983
    Date of Patent: August 13, 1985
    Assignee: Pfizer Inc.
    Inventor: Saul B. Kadin
  • Patent number: 4533667
    Abstract: A series of novel spiro-oxindole imidazolidinedione derivatives have been prepared, including their pharmaceutically acceptable salts. These compounds are useful in therapy as aldose reductose inhibitors for the control of certain chronic diabetic complications. Preferred compounds include 6'-amino-spiro-[imidazolidine-4,3'-indoline]-2,2',5-trione, 5'-chloro-7'-aminospiro-[imidazolidine-4,3'-indoline]-2,2',5-trione, 1'-(3-pyridylmethyl)-5'-fluoro-spiro-[imidazolidine-4,3'-indoline]-2,2',5- trione, 1'-(3-pyridylmethyl)-5',7'-dichloro-spiro-[imidazolidine-4,3'-indoline]-2, 2',5-trione and spiro-[imidazolidine-4,3'-(6-azaindoline)]-2,2',5-trione. Methods for preparing these compounds from known starting materials are provided.
    Type: Grant
    Filed: April 16, 1984
    Date of Patent: August 6, 1985
    Assignee: Pfizer Inc.
    Inventor: Alan J. Hutchison
  • Patent number: 4533709
    Abstract: Fumaric acid polymers may be used to control or inhibit scaling in boilers, desalination plants, steam generators, cooling equipment and the like. A novel process for their synthesis employs a mono or dialkyl ester of fumaric acid as a starting material.
    Type: Grant
    Filed: September 28, 1984
    Date of Patent: August 6, 1985
    Assignee: Pfizer Inc.
    Inventor: Stanley W. Walinsky